MedPath

Continuous Monitoring and Control of Hypoglycemia

Conditions
Diabetes
Interventions
Device: Continuous Glucose Monitoring (CGM)
Registration Number
NCT03340831
Lead Sponsor
DexCom, Inc.
Brief Summary

Evaluate safety of non-adjunctive CGM use in CGM naive participants.

Detailed Description

The study comprises recruitment and consenting of pediatric and adult participants. At entry, the following information will be collected: demographics, labs, clinical and diabetes history information (history of mild/severe hypoglycemia or DKA events in the past 6 months and SMBG testing frequency). There are 3 clinic visits: Study Entry, Month 6 and Month 12 . Monthly phone contacts will be made to assess for any mild/severe hypoglycemic or DKA events and any details surrounding an event. Clinic visits at Months 6 and 12 will capture frequency of SMBG testing, A1C level and PRO information. CGM data will be obtained during the study to assess for CGM adherence.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1388
Inclusion Criteria
  • Naïve to real-time CGM
  • Type 1 or insulin-requiring Type 2 diabetes
  • ≥ 2 years old
Exclusion Criteria
  • Use of RT-CGM, within the past 12 months
  • Pregnancy
  • Concomitant disease or condition that may compromise patient safety including and not limited to severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long term medical condition that would interfere with study related tasks or visits, or ongoing treatment for a significant malignancy.
  • Known (or suspected) significant allergy to medical grade adhesives
  • Dialysis

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CGM/BGM GroupContinuous Glucose Monitoring (CGM)single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 and G6 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
Primary Outcome Measures
NameTimeMethod
Change in hypoglycemic events6 months

Change in average number of hypoglycemic events per patient between CGM use compared to BGM use

Secondary Outcome Measures
NameTimeMethod
Change in A1C6 months

Percent change in A1C lab between CGM use period compared to BGM use period.

Change in incidence of hypoglycemic events6 months

Percent change of participants with at least one event between CGM use period compared to BGM use period.

Change in Hypoglycemia Confidence PRO scores6 months

Percent change in mean scores for the Hypoglycemia Confidence Scale between CGM use period compared to BGM use period.

Change in GMSS PRO scores6 months

Percent change in mean scores for the Glucose monitoring satisfaction survey (GMSS) \[Emotional and Trust subscales\] between CGM use period compared to BGM use period.

Change in Diabetes Distress Scale (DDS) PRO scores6 months

Percent change in mean scores for the DDS between CGM use period compared to BGM use period.

Change in Hypoglycemia Fear PRO scores6 months

Percent change in mean scores for the Hypoglycemia Fear Survey between CGM use period compared to BGM use period.

Trial Locations

Locations (25)

Scripps Whittier Diabetes Institute

🇺🇸

La Jolla, California, United States

Carteret Medical Group

🇺🇸

Morehead City, North Carolina, United States

Diabetes & Endocrinology Consultants, PC

🇺🇸

Morehead City, North Carolina, United States

Diabetes and Endocrine Associates

🇺🇸

La Mesa, California, United States

Mills-Peninsula Medical Center

🇺🇸

San Mateo, California, United States

Rocky Mountain Diabetes Center

🇺🇸

Idaho Falls, Idaho, United States

Mountain Diabetes and Endocrine Center

🇺🇸

Asheville, North Carolina, United States

Sansum Diabetes Research Institute

🇺🇸

Santa Barbara, California, United States

Intervent Clinical Research Center

🇺🇸

Pembroke Pines, Florida, United States

Atlanta Diabetes

🇺🇸

Atlanta, Georgia, United States

Northshore University Health System

🇺🇸

Skokie, Illinois, United States

International Diabetes Research Center

🇺🇸

Minneapolis, Minnesota, United States

Research Institute of Dallas

🇺🇸

Dallas, Texas, United States

Advanced Research Associates

🇺🇸

Ogden, Utah, United States

Cotton O'Neil Clinical Research

🇺🇸

Topeka, Kansas, United States

Vanderbilt Eskind Diabetes Clinic

🇺🇸

Nashville, Tennessee, United States

University of Oklahoma Health Sciences Center Department of Pediatric Diabetes and Endocrinology

🇺🇸

Oklahoma City, Oklahoma, United States

University of South Florida Clinical Research Center

🇺🇸

Tampa, Florida, United States

Methodist Physicians Clinic - Diabetes and Endocrine Specialists

🇺🇸

Omaha, Nebraska, United States

Amarillo Medical Specialists, LLP

🇺🇸

Amarillo, Texas, United States

Centre of Excellence in Diabetes and Endocrinology

🇺🇸

Sacramento, California, United States

Children's Mercy Hospital

🇺🇸

Kansas City, Missouri, United States

University of Florida Pediatric Endocrinology

🇺🇸

Gainesville, Florida, United States

Texas Diabetes and Endocrine

🇺🇸

Austin, Texas, United States

Iowa Diabetes & Endocrinology Research Center

🇺🇸

Des Moines, Iowa, United States

© Copyright 2025. All Rights Reserved by MedPath